Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem

Regeneron data show signs of activity with a new ovarian tumor target, and solidify company’s PD-1 position in skin cancer

Companies are testing 15 therapies across four mechanisms; five trials to report data this year

How Legend and Janssen gained the first FDA approval of a Chinese CAR T and what’s next for Legend’s pipeline

The targets and indications CAR T developers are exploring to get to efficacy in solid tumors

Sanofi’s new trispecific technology could provide a growth platform for the pharma’s cancer franchise